X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET

Company Participants

Dan Ferry - LifeSci Advisors

Paula Ragan - Chief Executive Officer

Diego Cadavid - Chief Medical Officer

Mark Baldry - Chief Commercial Officer

Murray Stewart - Interim Chief Medical Officer

Conference Call Participants

Stephen Willey - Stifel

Eva Privitera - Cowen

Mayank Mamtani - B. Riley Securities

Trevor Allred - Oppenheimer

Swayampakula Ramakanth - H.C. Wainwright

Operator

Greetings, and welcome to X4 Pharmaceuticals third quarter 2022 conference call. At this time, all participants are in a listen only mode. A question answer session will follow the formal presentation. As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.

Dan Ferry

Thank you, operator. And good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer Dr. Paula Ragan and Chief Medical Officer Diego Cadavid. We will also hear briefly from the company's new Chief Commercial Officer Mark Baldry and company board member and incoming interim Chief Medical Officer Dr. Murray Stewart. Following prepared remarks, we will open the call to your questions and will be joined by Chief Financial Officer Adam Mostafa, Chief Scientific Officer Art Taveras, and Chief Operating Officer Mary DiBiase.

As a reminder on today's call, the company will be making forward-looking statements regarding regulatory and product development plans as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4's most recent filings with the SEC, including this quarter's 10Q, which is expected to be filed after market close today.

I'd now like to turn the call over to X4's President and CEO Dr. Paula Ragan. Paula?

Paula Ragan

Thanks, Dan. And thank you everyone, for joining us on the call this morning. As we shared in the press release this morning, and as Dan just mentioned, Diego will be transitioning out of his role as Chief Medical Officer and becoming a senior medical consultant to X4. And our board member, Dr. Murray Stewart, former Chief Medical Officer of GSK and Rhythm Pharmaceuticals, will be joining X4 as interim CMO. At the end of today's call, Murray will say a few words of introduction. As we welcome new team members, we are extremely excited to share the progress that we've been making as we sharpen our focus of the company with a mission to develop therapeutics to treat the broad patient population with chronic neutropenic disorders, including our first potential indication of WHIM syndrome and where we believe there's a significant need for an oral efficacious therapy with low treatment burden and good tolerability.